To investigate the potential activity of the BCL2 inhibitor venetoclax in APL cells, ATO-sensitive and ATO-resistant clones, as well as the NB4 bulk cell line, were exposed to increasing concentrations of the drug. The gene discussed is BCL2; the disease is acute promyelocytic leukemia.